Literature DB >> 15039037

Amnestic MCI or prodromal Alzheimer's disease?

Bruno Dubois1, Martin L Albert.   

Abstract

The concept of mild cognitive impairment (MCI) draws attention to cognitive changes not severe enough to warrant the diagnosis of dementia. As used today, it covers many pathological disorders and characterises a diverse population of patients who attend memory clinics. Our concern is the underlying heterogeneity. We suggest that it will soon be possible (if it is not already) to identify the underlying pathological disorders before the affected patients meet the criteria of dementia, thanks to specific neuropsychological assessments, neuroimaging, and biomarkers. In particular, patients with Alzheimer's disease (AD), the most important subgroup of patients with MCI, can already be identified before appearance of the fully developed clinical dementia syndrome. Accordingly, this paper proposes diagnostic criteria for "prodromal AD".

Entities:  

Mesh:

Year:  2004        PMID: 15039037     DOI: 10.1016/S1474-4422(04)00710-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  118 in total

1.  Recall termination in free recall.

Authors:  Jonathan F Miller; Christoph T Weidemann; Michael J Kahana
Journal:  Mem Cognit       Date:  2012-01-31

2.  Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data.

Authors:  Youngsang Cho; Joon-Kyung Seong; Yong Jeong; Sung Yong Shin
Journal:  Neuroimage       Date:  2011-10-08       Impact factor: 6.556

3.  Cerebellar atrophy in patients with subcortical-type vascular cognitive impairment.

Authors:  Cindy W Yoon; Sang Won Seo; Jun-Sung Park; Ki-Chang Kwak; Uicheul Yoon; Mee Kyung Suh; Geon Ha Kim; Ji Soo Shin; Chi Hun Kim; Young Noh; Hanna Cho; Min-Jeong Kim; Jong Hun Kim; Jee Hoon Roh; Jong-Min Lee; Duk L Na
Journal:  Cerebellum       Date:  2013-02       Impact factor: 3.847

Review 4.  Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease.

Authors:  F Portet; P J Ousset; P J Visser; G B Frisoni; F Nobili; Ph Scheltens; B Vellas; J Touchon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-20       Impact factor: 10.154

Review 5.  MNESIS: towards the integration of current multisystem models of memory.

Authors:  Francis Eustache; Béatrice Desgranges
Journal:  Neuropsychol Rev       Date:  2008-02-29       Impact factor: 7.444

6.  Interest of the new criteria for drug trials in AD.

Authors:  B Dubois
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

7.  When does cognitive decline begin? A systematic review of change point studies on accelerated decline in cognitive and neurological outcomes preceding mild cognitive impairment, dementia, and death.

Authors:  Justin E Karr; Raquel B Graham; Scott M Hofer; Graciela Muniz-Terrera
Journal:  Psychol Aging       Date:  2018-03

8.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 9.  Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia.

Authors:  Howard Chertkow; Fadi Massoud; Ziad Nasreddine; Sylvie Belleville; Yves Joanette; Christian Bocti; Valérie Drolet; John Kirk; Morris Freedman; Howard Bergman
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

10.  Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease.

Authors:  Montse Alegret; Mercè Boada-Rovira; Georgina Vinyes-Junqué; Sergi Valero; Ana Espinosa; Isabel Hernández; Gemma Modinos; Maitee Rosende-Roca; Ana Mauleón; James T Becker; Lluís Tárraga
Journal:  J Clin Exp Neuropsychol       Date:  2009-01-14       Impact factor: 2.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.